Thymosin Alpha-1

International journal of molecular sciences · 2025

Researchers observed that aging leads to a decline in immune function due to the shrinking of the thymus gland, which affects T-cell production. The review highlights thymosin alpha-1 (Tα1), a peptide hormone that can enhance immune response and reduce inflammation in older adults. The findings suggest that Tα1 may improve vaccine effectiveness and counteract age-related immune decline.

• Researchers found that thymic involution contributes to reduced T-cell production and increased vulnerability to diseases in older adults.
• The study highlighted thymosin alpha-1 (Tα1) as a peptide hormone with immune-boosting and anti-inflammatory effects.
• Evidence from studies indicated that Tα1 can enhance vaccine responses in the elderly and help mitigate the effects of immunosenescence.

The Journal of infectious diseases · 2023

Researchers studied the effects of thymalfasin (Thymosin-α-1) on hospitalized COVID-19 patients experiencing low oxygen levels and low lymphocyte counts. They observed that thymalfasin may help increase certain immune cells more quickly than standard treatments, although the overall recovery rates were not significantly different between groups.

• Researchers found that patients receiving thymalfasin had a higher average increase in CD4+ T cells after five days compared to those receiving standard care.
• The study included 49 hospitalized patients with hypoxemia and lymphocytopenia due to COVID-19.
• Nine serious adverse events occurred in treated patients, but these were not linked to thymalfasin.

Cancer research · 2022

Researchers found that thymosin α-1 (Tα-1) can change the behavior of certain immune cells in the breast tumor environment after chemotherapy. This change helps improve the effectiveness of chemotherapy by enhancing the immune response against tumors. The study suggests that Tα-1 could be beneficial when given after chemotherapy in breast cancer patients.

• Tα-1 reverses the M2 polarization of tumor-associated macrophages during the clearance of dying tumor cells.
• Tα-1 enhances the function of immune cells, specifically CD4+ and CD8+ T cells, in the tumor environment.
• Combining Tα-1 with chemotherapy significantly suppresses tumor growth in a breast cancer model.

Endocrine · 2019

Researchers reviewed recent developments in thyroid hormone signaling, focusing on new compounds called 'novel thyroid hormones.' They found that these hormones, particularly T1AM, may function as independent chemical messengers with potential effects on metabolism and brain function.

• Researchers observed that novel thyroid hormones like T1AM and T2 could play significant roles in metabolism and brain health.
• The study highlighted T1AM as the most promising candidate for further research due to its intriguing effects.
• Additionally, researchers noted potential therapeutic applications for these hormones in conditions like obesity, dementia, and thyroid hormone resistance syndromes.

Expert opinion on biological therapy · 2018

Researchers studied thymosin alpha 1 (Ta1), a peptide hormone important for immune system regulation. They found that lower levels of Ta1 are associated with various health conditions, including certain autoimmune diseases and infections, suggesting its potential role in monitoring and enhancing immune responses.

• Researchers observed that patients with diseases like hepatitis B, psoriatic arthritis, and multiple sclerosis have significantly lower serum levels of Ta1 compared to healthy individuals.
• The study noted that cystic fibrosis patients also show reduced Ta1 levels in their sputum.
• Evidence suggests that understanding a patient's baseline Ta1 levels is crucial for developing effective treatment protocols.

Vitamins and hormones · 2016

Researchers studied thymosin alpha 1 (Ta1), a peptide that boosts immune function, particularly in cases of immune suppression due to aging or diseases like infections and cancer. The review highlights how Ta1 activates various immune cells and stimulates the production of important immune signals, showing promise for improving immune responses.

• Researchers observed that Ta1 affects multiple immune cell types involved in immune suppression.
• The study found that Ta1 activates signaling pathways in immune cells, leading to increased production of immune-related cytokines.
• Extensive preclinical and clinical studies suggest Ta1's potential for enhancing immune function in various health conditions.

Expert opinion on biological therapy · 2015

Researchers observed that thymosin alpha-1 (Tα-1) can enhance the immune response in patients with chronic hepatitis B (CHB), potentially helping to control the virus. The study reviewed various articles and found that Tα-1 is effective in reducing viral replication, especially when used in combination with other treatments.

• Tα-1 monotherapy effectively suppresses viral replication compared to untreated patients or conventional interferon.
• Combination therapy of Tα-1 with lamivudine or interferon-alpha showed improved results in reducing HBV DNA levels and achieving HBeAg seroconversion.
• Ongoing studies are exploring the effects of Tα-1 combined with entecavir in patients with HBV-related cirrhosis.

Journal of gastroenterology and hepatology · 2004

Researchers studied the use of thymalfasin, an immunoregulatory agent, in patients with chronic hepatitis B, a widespread viral infection affecting millions. They found that thymalfasin may enhance immune responses and improve treatment outcomes, especially when combined with other therapies like interferon.

• Chronic hepatitis B affects approximately 350 million people globally, with a significant concentration in the Asia-Pacific region.
• Current treatments like interferon and antiviral agents show limited effectiveness, particularly in certain patient groups.
• Thymalfasin has the potential to boost immune function and is being tested in combination with existing therapies, showing promising results.

Journal of gastroenterology and hepatology · 2004

Researchers studied thymalfasin, an immunoregulatory agent, as a potential therapy for chronic hepatitis B, a serious global health issue affecting around 350 million people. They found that thymalfasin may enhance immune responses and improve T-cell function, showing promise in both standalone and combination treatments with interferon.

• Chronic hepatitis B virus infection is a significant health concern, especially in the Asia-Pacific region.
• Thymalfasin has the potential to improve immune responses in patients with chronic hepatitis B.
• Ongoing studies are exploring the effectiveness of thymalfasin alone and in combination with interferon.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2001

Researchers reviewed thymosin alpha-1 (TA1), a synthetic polypeptide, and its effects on hepatitis B and C. The study found mixed results regarding TA1's effectiveness, with some patients showing improvements in virus clearance, particularly when combined with another treatment for hepatitis C.

• In clinical trials for hepatitis B, 40.6% of patients treated with TA1 showed virus clearance compared to 9.4% in untreated controls.
• For hepatitis C, combination therapy with TA1 and interferon resulted in 71% of patients achieving normal liver enzyme levels, compared to 35% with interferon alone.
• TA1 was generally well tolerated, with most side effects being mild and localized.